Switch to:
Valeant Pharmaceuticals International Inc (NYSE:VRX)
Research and Development
$239 Mil (TTM As of Sep. 2015)

This is the expense the company spent on research and development. Valeant Pharmaceuticals International Inc's research and development for the three months ended in Sep. 2015 was $102 Mil. Its research and development for the trailing twelve months (TTM) ended in Sep. 2015 was $239 Mil.


Definition

This is the expense the company spent on research and development.

Valeant Pharmaceuticals International Inc Research & Development for the trailing twelve months (TTM) ended in Sep. 2015 was 0 (Dec. 2014 ) + 55.8 (Mar. 2015 ) + 81.1 (Jun. 2015 ) + 101.6 (Sep. 2015 ) = $239 Mil.

* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.


Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


Related Terms

Gross Profit


Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.

Valeant Pharmaceuticals International Inc Annual Data

Dec05Dec06Dec07Dec08Dec09Dec10Dec11Dec12Dec13Dec14
Research & Development 88951189310715817579157246

Valeant Pharmaceuticals International Inc Quarterly Data

Jun13Sep13Dec13Mar14Jun14Sep14Dec14Mar15Jun15Sep15
Research & Development 2549061675905681102
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GuruFocus Premium Plus Membership

FEEDBACK